Literature DB >> 30673508

Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Rachel K Putman1, Gunnar Gudmundsson2,3, Gisli Thor Axelsson3,4, Tomoyuki Hida5,6, Osamu Honda7, Tetsuro Araki5,6, Masahiro Yanagawa7, Mizuki Nishino5,6, Ezra R Miller1, Gudny Eiriksdottir4, Elías F Gudmundsson4, Noriyuki Tomiyama7, Hiroshi Honda8, Ivan O Rosas1, George R Washko1,6, Michael H Cho1,9, David A Schwartz10, Vilmundur Gudnason4, Hiroto Hatabu5,6, Gary M Hunninghake1,6.   

Abstract

Rationale: Interstitial lung abnormalities (ILA) are radiologic abnormalities on chest computed tomography scans that have been associated with an early or mild form of pulmonary fibrosis. Although ILA have been associated with radiologic progression, it is not known if specific imaging patterns are associated with progression or risk of mortality.
Objectives: To determine the role of imaging patterns on the risk of death and ILA progression.
Methods: ILA (and imaging pattern) were assessed in 5,320 participants from the AGES-Reykjavik Study, and ILA progression was assessed in 3,167 participants. Multivariable logistic regression was used to assess factors associated with ILA progression, and Cox proportional hazards models were used to assess time to mortality. Measurements and Main
Results: Over 5 years, 327 (10%) had ILA on at least one computed tomography, and 1,435 (45%) did not have ILA on either computed tomography. Of those with ILA, 238 (73%) had imaging progression, whereas 89 (27%) had stable to improved imaging; increasing age and copies of MUC5B genotype were associated with imaging progression. The definite fibrosis pattern was associated with the highest risk of progression (odds ratio, 8.4; 95% confidence interval, 2.7-25; P = 0.0003). Specific imaging patterns were also associated with an increased risk of death. After adjustment, both a probable usual interstitial pneumonia and usual interstitial pneumonia pattern were associated with an increased risk of death when compared with those indeterminate for usual interstitial pneumonia (hazard ratio, 1.7; 95% confidence interval, 1.2-2.4; P = 0.001; hazard ratio, 3.9; 95% confidence interval, 2.3-6.8;P < 0.0001), respectively. Conclusions: In those with ILA, imaging patterns can be used to help predict who is at the greatest risk of progression and early death.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; imaging pattern; interstitial lung abnormalities; mortality; progression

Mesh:

Substances:

Year:  2019        PMID: 30673508      PMCID: PMC6635786          DOI: 10.1164/rccm.201809-1652OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  25 in total

1.  Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study.

Authors:  David J Lederer; Paul L Enright; Steven M Kawut; Eric A Hoffman; Gary Hunninghake; Edwin J R van Beek; John H M Austin; Rui Jiang; Gina S Lovasi; R Graham Barr
Journal:  Am J Respir Crit Care Med       Date:  2009-06-19       Impact factor: 21.405

2.  Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome.

Authors:  Rachel K Putman; Gary M Hunninghake; Paul B Dieffenbach; Diana Barragan-Bradford; Karolina Serhan; Ursula Adams; Hiroto Hatabu; Mizuki Nishino; Robert F Padera; Laura E Fredenburgh; Rebecca M Baron; Joshua A Englert
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

3.  Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial.

Authors:  Esther Pompe; Pim A de Jong; David A Lynch; Nikolas Lessmann; Ivana Išgum; Bram van Ginneken; Jan-Willem J Lammers; Firdaus A A Mohamed Hoesein
Journal:  Eur Respir J       Date:  2017-04-19       Impact factor: 16.671

4.  High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study.

Authors:  Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Eric A Hoffman; Hilary F Armstrong; John H M Austin; Robert C Basner; Matthew N Bartels; Jason D Christie; Paul L Enright; Bernadette R Gochuico; Karen Hinckley Stukovsky; Joel D Kaufman; P Hrudaya Nath; John D Newell; Scott M Palmer; Dan Rabinowitz; Ganesh Raghu; Jessica L Sell; Jered Sieren; Sushil K Sonavane; Russell P Tracy; Jubal R Watts; Kayleen Williams; Steven M Kawut; David J Lederer
Journal:  Eur Respir J       Date:  2016-07-28       Impact factor: 16.671

5.  Interstitial lung diseases in a lung cancer screening trial.

Authors:  N Sverzellati; L Guerci; G Randi; E Calabrò; C La Vecchia; A Marchianò; A Pesci; M Zompatori; U Pastorino
Journal:  Eur Respir J       Date:  2011-01-13       Impact factor: 16.671

6.  MUC5B promoter polymorphism and interstitial lung abnormalities.

Authors:  Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

7.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

8.  Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study.

Authors:  Tetsuro Araki; Rachel K Putman; Hiroto Hatabu; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; David A Schwartz; Ivan O Rosas; George R Washko; George T O'Connor; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

9.  Lung volumes and emphysema in smokers with interstitial lung abnormalities.

Authors:  George R Washko; Gary M Hunninghake; Isis E Fernandez; Mizuki Nishino; Yuka Okajima; Tsuneo Yamashiro; James C Ross; Raúl San José Estépar; David A Lynch; John M Brehm; Katherine P Andriole; Alejandro A Diaz; Ramin Khorasani; Katherine D'Aco; Frank C Sciurba; Edwin K Silverman; Hiroto Hatabu; Ivan O Rosas
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more
  34 in total

1.  Baseline Characteristics and Progression of a Spectrum of Interstitial Lung Abnormalities and Disease in Rheumatoid Arthritis.

Authors:  Leticia Kawano-Dourado; Tracy J Doyle; Karina Bonfiglioli; Márcio V Y Sawamura; Renato H Nakagawa; Fábio E Arimura; Hye J Lee; Diana Arrais de Souza Rangel; Cleonice Bueno; Carlos R R Carvalho; Maria Laura Sabbag; Camila Molina; Ivan O Rosas; Ronaldo A Kairalla
Journal:  Chest       Date:  2020-05-16       Impact factor: 9.410

2.  Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease.

Authors:  Margaret L Salisbury; Justin C Hewlett; Guixiao Ding; Cheryl R Markin; Katrina Douglas; Wendi Mason; Adam Guttentag; John A Phillips; Joy D Cogan; Sara Reiss; Daphne B Mitchell; Pingsheng Wu; Lisa R Young; Lisa H Lancaster; James E Loyd; Stephen M Humphries; David A Lynch; Jonathan A Kropski; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

3.  Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.

Authors:  Hiroto Hatabu; Gary M Hunninghake; Luca Richeldi; Kevin K Brown; Athol U Wells; Martine Remy-Jardin; Johny Verschakelen; Andrew G Nicholson; Mary B Beasley; David C Christiani; Raúl San José Estépar; Joon Beom Seo; Takeshi Johkoh; Nicola Sverzellati; Christopher J Ryerson; R Graham Barr; Jin Mo Goo; John H M Austin; Charles A Powell; Kyung Soo Lee; Yoshikazu Inoue; David A Lynch
Journal:  Lancet Respir Med       Date:  2020-07       Impact factor: 30.700

4.  Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis.

Authors:  Gary M Hunninghake; Luisa D Quesada-Arias; Nikkola E Carmichael; Jose M Martinez Manzano; Sergio Poli De Frías; Maura Alvarez Baumgartner; Lisa DiGianni; Shannon N Gampala-Sagar; Dominick A Leone; Swati Gulati; Souheil El-Chemaly; Hilary J Goldberg; Rachel K Putman; Hiroto Hatabu; Benjamin A Raby; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

Review 5.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

6.  Hiatus hernia and interstitial lung abnormalities.

Authors:  Peter M George; Tomoyuki Hida; Rachel K Putman; Takuya Hino; Sujal R Desai; Anand Devaraj; Sacheen Kumar; John A Mackintosh; Vilmundur Gudnason; Hiroto Hatabu; Gunnar Gudmundsson; Gary M Hunninghake
Journal:  Eur Respir J       Date:  2020-11-19       Impact factor: 16.671

7.  Interstitial Lung Abnormalities, Emphysema, and Spirometry in Smokers.

Authors:  Aravind A Menon; Rachel K Putman; Jason L Sanders; Takuya Hino; Akinori Hata; Mizuki Nishino; Auyon J Ghosh; Samuel Y Ash; Ivan O Rosas; Michael H Cho; David A Lynch; George R Washko; Edwin K Silverman; Hiroto Hatabu; Gary M Hunninghake
Journal:  Chest       Date:  2021-11-03       Impact factor: 9.410

8.  Traction Bronchiectasis/Bronchiolectasis is Associated with Interstitial Lung Abnormality Mortality.

Authors:  Tomoyuki Hida; Mizuki Nishino; Takuya Hino; Junwei Lu; Rachel K Putman; Elias F Gudmundsson; Tetsuro Araki; Vladimir I Valtchinov; Osamu Honda; Masahiro Yanagawa; Yoshitake Yamada; Akinori Hata; Masahiro Jinzaki; Noriyuki Tomiyama; Hiroshi Honda; Raul San Jose Estepar; George R Washko; Takeshi Johkoh; David C Christiani; David A Lynch; Vilmundur Gudnason; Gunnar Gudmundsson; Gary M Hunninghake; Hiroto Hatabu
Journal:  Eur J Radiol       Date:  2020-05-18       Impact factor: 3.528

9.  Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series.

Authors:  Ioana A Dobre; Angela J Frank; Kristin M D'Silva; David C Christiani; Daniel Okin; Amita Sharma; Sydney B Montesi
Journal:  Clin Lung Cancer       Date:  2021-02-04       Impact factor: 4.785

10.  The associations of interstitial lung abnormalities with cancer diagnoses and mortality.

Authors:  Gisli T Axelsson; Rachel K Putman; Thor Aspelund; Elias F Gudmundsson; Tomayuki Hida; Tetsuro Araki; Mizuki Nishino; Hiroto Hatabu; Vilmundur Gudnason; Gary M Hunninghake; Gunnar Gudmundsson
Journal:  Eur Respir J       Date:  2020-12-17       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.